WilmerHale Advises General Catalyst in Capital Rx's Series C Funding

Download IconDownload Print IconPrint

WilmerHale Advises General Catalyst in Capital Rx's Series C Funding

Client News

Related Solutions

Helping clients launch their businesses and transform their innovative ideas into successful companies.
Comprehensive counseling for healthcare providers, insurers and the companies that supply them with products and services.
Offering a sophisticated, full-service solution to private equity sponsors and entrepreneurs, from initial investment to exit.

On June 13, 2022, Capital Rx, a health technology company, announced that it has secured $106M in Series C funding. General Catalyst, a venture capital firm specializing in early-stage and growth equity investments, was among the investors that contributed to the round of funding. The funding will be used to advance Capital Rx's mission of modernizing prescription and healthcare infrastructure to increase operational efficiency and improve patient care.

The WilmerHale team advising General Catalyst was led by Jason Kropp and Jahnvi Desai.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel